Cliniciansʼ Use of Intravaginal Boric Acid Maintenance Therapy for Recurrent Vulvovaginal Candidiasis and Bacterial Vaginosis

Background. Recurrent vulvovaginal candidiasis (RVC) is an increasing challenge in clinical practice. Objective. The purpose of this study was to reduce the episodes of RVC through the intake of fluconazole 200 mg/dose with a personalized regimen at growing administration intervals with a probiotic. Method. 55 patients received a 200 mg fluconazole as an induction dose for 3 alternate days. Symptoms resolution after 10–14 days made the patients eligible to continue with a maintenance therapy of fluconazole weekly for one month, followed by 200 mg after 10, 15, 20 and 30 days. Patients were allowed to move on to the next level of maintenance therapy only if they were symptom free. Patients were also given a probiotic with Beta Glucan and Echinacea Purpurea. Results. Among the 55 patients enrolled, four (7%) have withdrawn after the induction phase. 51 patients completed the whole therapeutic maintenance period, and eight (15,6%) experienced a recurrence before the end of the therapy. Five women (9,8%) relapsed (two after 2 months and three after 6 months). Conclusion. The positive results of our study prove the effectiveness of an individualized protocol for a rather short period, with a slowly decreasing administration of fluconazole + probiotic.

Download Full-text

Boric Acid for Recurrent Vulvovaginal Candidiasis: The Clinical Evidence

Journal of Women s Health ◽

10.1089/jwh.2010.2708 ◽

2011 ◽

Vol 20 (8) ◽

pp. 1245-1255 ◽

Cited By ~ 45

Author(s):

Christos Iavazzo ◽

Ioannis D. Gkegkes ◽

Ioanna M. Zarkada ◽

Matthew E. Falagas

Keyword(s):

Boric Acid ◽

Clinical Evidence ◽

Vulvovaginal Candidiasis ◽

Recurrent Vulvovaginal Candidiasis

Download Full-text

How Vaginal Infections Impact Women’s Everyday Life <br/>—Women’s Lived Experiences of Bacterial Vaginosis and Recurrent Vulvovaginal Candidiasis

Advances in Sexual Medicine ◽

10.4236/asm.2017.71001 ◽

2017 ◽

Vol 07 (01) ◽

pp. 1-19 ◽

Cited By ~ 3

Author(s):

Annsofie Adolfsson ◽

Anna Hagander ◽

Farzane Mahjoubipour ◽

Per-Göran Larsson

Keyword(s):

Bacterial Vaginosis ◽

Everyday Life ◽

Lived Experiences ◽

Vulvovaginal Candidiasis ◽

Vaginal Infections ◽

Recurrent Vulvovaginal Candidiasis

Download Full-text

The efficacy of the boric acid-based maintenance therapy in preventing recurrent vulvovaginal candidiasis

Journal of Experimental and Clinical Medicine ◽

10.52142/omujecm.38.4.11 ◽

2021 ◽

Vol 38 (4) ◽

pp. 461-465

Author(s):

Üzeyir KALKAN ◽

Murat YASSA ◽

Kemal SANDAL ◽

Arzu Bilge TEKİN ◽

Ceyhun KILINÇ ◽

...

Keyword(s):

Boric Acid ◽

Lifestyle Changes ◽

Vulvovaginal Candidiasis ◽

Antifungal Drugs ◽

First Year ◽

Recurrence Rates ◽

Recurrent Vulvovaginal Candidiasis ◽

Life Style Changes ◽

Treatment Package ◽

Vaginal Estriol

Current gold-standard treatment of recurrent vulvovaginal candidiasis (RVVC) is mainly based on maintenance with fluconazole. Moderate to high recurrence rates at long-term use and secondary fluconazole resistance emerge as reasons to seek for new topical maintenance regimens. In this study, it is aimed to assess the efficacy and safety of boric acid-based treatment approach to treat clinical RVVC. In this retrospective study, patients who were diagnosed with RVVC received a treatment package for six months that consist of induction with boric acid vaginal suppositories 600 mg daily for 14 nights followed by maintenance for five nights starting with every fifth day of the menstrual cycles; a vaginal estriol-lactobacilli combination; and several rigorous life-style changes. The success was defined as the absence of symptomatic recurrence during the follow-up. Success rate at the first year was found to be 94.8% in a total of 173 patients. Mild, reversible side effects were observed in five patients (2.9%). Boric acid, along with a vaginal estriol-lactobacilli combination and lifestyle changes can be a safe and effective alternative in lieu of potent systemic antifungal drugs as a first-line treatment for the patients referred with RVVC.

Download Full-text

Laboratory evaluation of the etiology of pathological vaginal dischurge

HEALTH OF WOMAN ◽

10.15574/hw.2019.140.64 ◽

2019 ◽

pp. 64-68

Author(s):

O.A. Burka ◽

◽

T.M. Tutchenko ◽

Keyword(s):

Bacterial Vaginosis ◽

Crucial Role ◽

Inflammatory Process ◽

Vaginal Discharge ◽

Vulvovaginal Candidiasis ◽

Diagnostic Methods ◽

Laboratory Evaluation ◽

Aerobic Vaginitis ◽

Laboratory Confirmation ◽

Vaginal Secretions

Pathological vaginal discharge is one of the most common complaints in women of all ages. Today, gynecologists are increasingly faced with a problem when, in the absence of laboratory confirmation of vulvovaginal candidiasis, bacterial vaginosis and STIs, women complain of discomfort caused by vaginal secretions. Causes of pathological vaginal discharge can be infectious and non-infectious processes and their combinations. The article analyzes the causes of the difficulties of diagnosing the of pathological vaginal discharge ethiology, demonstrates how the application of adequate volume of modern laboratory diagnostic methods in combination with understanding the multifaceted components of the inflammatory process plays crucial role in finding out the etiology of pathological vaginal secretions and the choice of optimal therapeutic tactics. Key words: pathological vaginal dischurge, vaginal microbiota, vulvovaginal candidiasis, bacterial vaginosis, aerobic vaginitis, cytolytic vaginosis.

Download Full-text